Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880209 | 1.00 | PTPN2 (0.40) | PTPN2PTPN1PTPN6ALOX5DHODH | |
| SCHEMBL22863341 | 0.91 | PTPN2 (0.38) | PTPN2PTPN1PTPN6ALOX5DHODH | |
| SCHEMBL22863342 | 0.91 | PTPN2 (0.38) | PTPN2PTPN1PTPN6ALOX5DHODH | |
| SCHEMBL22863326 | 0.88 | APP (0.35) | PTPN1ALOX5APPBACE1 | |
| SCHEMBL15744228 | 0.88 | APP (0.35) | PTPN1ALOX5APPBACE1 | |
| SCHEMBL9880208 | 0.88 | APP (0.35) | PTPN1ALOX5APPBACE1 | |
| SCHEMBL29406722 | 0.88 | APP (0.35) | PTPN1ALOX5APPBACE1 | |
| SCHEMBL21538153 | 0.86 | ALOX5 (0.46) | PTPN2PTPN1PTPN6ALOX5 | |
| SCHEMBL22863219 | 0.82 | PTPN2 (0.42) | PTPN2PTPN1PTPN6ALOX5DHODH | |
| SCHEMBL22863224 | 0.82 | ALOX5 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12457569-B2 | SMTC2-LP based RRM enhancement | APPLE INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2025-10-28 | — | — | US | disclosed |
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA MEDICAL UNIVERSITY (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | SHOWA UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| US-12052217-B2 | Methods and apparatus for service discovery | TELEFONAKTIEBOLAGET LM ERICSSON (SE) | 2024-07-30 | — | — | US | disclosed |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240107469-A1 | SMTC2-LP BASED RRM ENHANCEMENT | APPLE INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-11930460-B2 | SMTC2-LP based RRM enhancement | APPLE INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11850232-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | BIOGEN MA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-116982338-A | RRM enhancement based on SMTC2-LP | 苹果公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230092295-A1 | SMTC2-LP BASED RRM ENHANCEMENT | APPLE INC. | 2023-03-23 | — | — | US | disclosed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115225356-A | Method for rapidly detecting intrusion detection library | 北京威努特技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220294760-A1 | METHODS AND APPARATUS FOR SERVICE DISCOVERY | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2022-09-15 | — | — | US | disclosed |
| WO-2022151375-A1 | SMTC2-LP BASED RRM ENHANCEMENT | APPLE INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-3963868-A1 | METHODS AND APPARATUS FOR SERVICE DISCOVERY | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2022-03-09 | — | — | EP | disclosed |
| US-11265376-B2 | Migration project automation, e.g., automated selling, planning, migration and configuration of email systems | SKYKICK, LLC (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | PTPN2 2956/4885PTPN1 3029/4885PTPN6 2677/4885 |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | REN, ATP6V1B1, SLC10A1 | PTPN2 2956/4885PTPN1 3029/4885PTPN6 2677/4885 |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | PROC, FABP7, SERPINC1 | PTPN2 4604/4885PTPN1 4588/4885PTPN6 4480/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | PTPN2 2545/4885PTPN1 2665/4885PTPN6 1905/4885 |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, SERPINC1 | PTPN2 4604/4885PTPN1 4588/4885PTPN6 4480/4885 |
| US-11850232-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | PROC, FABP7, SERPINC1 | PTPN2 4604/4885PTPN1 4588/4885PTPN6 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.